JP5656407B2 - ビス−スルフヒドリル大環状化系 - Google Patents

ビス−スルフヒドリル大環状化系 Download PDF

Info

Publication number
JP5656407B2
JP5656407B2 JP2009541617A JP2009541617A JP5656407B2 JP 5656407 B2 JP5656407 B2 JP 5656407B2 JP 2009541617 A JP2009541617 A JP 2009541617A JP 2009541617 A JP2009541617 A JP 2009541617A JP 5656407 B2 JP5656407 B2 JP 5656407B2
Authority
JP
Japan
Prior art keywords
peptidomimetic
macrocycle
carbon
alkyl
peptidomimetic macrocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513314A (ja
JP2010513314A5 (cg-RX-API-DMAC7.html
Inventor
ナッシュ，ヒュー，エム．
Original Assignee
エイルロン セラピューティクス，インコーポレイテッド
エイルロン セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイルロン セラピューティクス，インコーポレイテッド, エイルロン セラピューティクス，インコーポレイテッド filed Critical エイルロン セラピューティクス，インコーポレイテッド
Publication of JP2010513314A publication Critical patent/JP2010513314A/ja
Publication of JP2010513314A5 publication Critical patent/JP2010513314A5/ja
Application granted granted Critical
Publication of JP5656407B2 publication Critical patent/JP5656407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009541617A 2006-12-14 2007-12-14 ビス−スルフヒドリル大環状化系 Expired - Fee Related JP5656407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87481906P 2006-12-14 2006-12-14
US60/874,819 2006-12-14
PCT/US2007/087615 WO2008076904A1 (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014163070A Division JP5931975B2 (ja) 2006-12-14 2014-08-08 ビス−スルフヒドリル大環状化系

Publications (3)

Publication Number Publication Date
JP2010513314A JP2010513314A (ja) 2010-04-30
JP2010513314A5 JP2010513314A5 (cg-RX-API-DMAC7.html) 2011-02-10
JP5656407B2 true JP5656407B2 (ja) 2015-01-21

Family

ID=39536693

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009541617A Expired - Fee Related JP5656407B2 (ja) 2006-12-14 2007-12-14 ビス−スルフヒドリル大環状化系
JP2014163070A Expired - Fee Related JP5931975B2 (ja) 2006-12-14 2014-08-08 ビス−スルフヒドリル大環状化系
JP2016089950A Expired - Fee Related JP6259861B2 (ja) 2006-12-14 2016-04-27 ビス−スルフヒドリル大環状化系

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014163070A Expired - Fee Related JP5931975B2 (ja) 2006-12-14 2014-08-08 ビス−スルフヒドリル大環状化系
JP2016089950A Expired - Fee Related JP6259861B2 (ja) 2006-12-14 2016-04-27 ビス−スルフヒドリル大環状化系

Country Status (9)

Country Link
US (5) US7960506B2 (cg-RX-API-DMAC7.html)
EP (2) EP3170835A1 (cg-RX-API-DMAC7.html)
JP (3) JP5656407B2 (cg-RX-API-DMAC7.html)
CN (2) CN105061577A (cg-RX-API-DMAC7.html)
AU (1) AU2007333846B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720306A2 (cg-RX-API-DMAC7.html)
CA (1) CA2686827C (cg-RX-API-DMAC7.html)
IL (1) IL199301A (cg-RX-API-DMAC7.html)
WO (1) WO2008076904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CA2830063C (en) * 2003-11-05 2017-10-31 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
AU2007319193A1 (en) 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR20160061439A (ko) * 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP5883220B2 (ja) * 2007-05-02 2016-03-09 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 細胞のホメオスタシス経路および細胞の生存を調節する方法
JP5653219B2 (ja) * 2007-12-31 2015-01-14 ニューヨーク ユニバーシティ 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御
JP2011511076A (ja) * 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009149214A2 (en) * 2008-06-03 2009-12-10 Aileron Therapeutics, Inc. Compositions and methods for enhancing cellular transport of biomolecules
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
WO2010033617A2 (en) * 2008-09-16 2010-03-25 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
WO2010034034A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034026A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920889A2 (pt) * 2008-09-22 2017-10-10 Aileron Therapeutics Inc macrociclos peptidomiméticos.
EP2331567A1 (en) * 2008-09-22 2011-06-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9206223B2 (en) 2008-09-22 2015-12-08 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
BRPI0918833A2 (pt) * 2008-09-22 2015-12-08 Aileron Therapeutics Inc macrociclos peptidomiméticos
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
US8653036B2 (en) 2009-02-27 2014-02-18 Mimetogen Pharmaceuticals Inc. Methods of treating retinitis pigmentosa
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
US20110223149A1 (en) * 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US10822374B2 (en) 2010-11-12 2020-11-03 Dana-Farber Cancer Institute, Inc. Cancer therapies and diagnostics
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
EP2670418A4 (en) * 2011-02-04 2015-06-17 Aegis Therapeutics Llc ORAL BIO-AVAILABLE PEPTIDARY MATERIAL COMPOSITIONS AND METHOD THEREFOR
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6450191B2 (ja) * 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
WO2013126703A1 (en) * 2012-02-22 2013-08-29 New York University Reversibly crosslinked helical hydrogen bond surrogate macrocycles
US9556229B2 (en) 2012-05-18 2017-01-31 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
DK2920197T3 (da) 2012-09-26 2021-05-31 Harvard College Prolinlåste sammenhæftede peptider og anvendelser deraf
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
BR112015022872A2 (pt) 2013-03-13 2017-11-07 Harvard College polipeptídeos grampeados e costurados, seu uso, seu método de preparação, composição que os compreende e aminoácido
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
AU2014234314B2 (en) 2013-03-21 2018-02-15 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2014201370A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
BR112016009443A8 (pt) * 2013-10-28 2020-03-24 Naurex Inc moduladores do receptor de nmda, pró-drogas e seus sais
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US10294273B2 (en) * 2014-04-02 2019-05-21 University Of Rochester Macrocyclic peptidomimetics for alpha-helix mimicry
AU2015264122B2 (en) 2014-05-21 2021-02-04 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
SG11201702223UA (en) * 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016049355A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
US11155577B2 (en) 2015-06-22 2021-10-26 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
WO2018017485A1 (en) 2016-07-17 2018-01-25 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020041270A1 (en) 2018-08-20 2020-02-27 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
US11345725B2 (en) 2019-09-16 2022-05-31 Research Foundation Of The City University Of New York Bis-thioether stapled peptides as inhibitors of PRC2 function
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
WO2025040657A1 (en) * 2023-08-21 2025-02-27 Medizinische Universität Wien Selective cyclized peptide kappa-opioid receptor antagonists

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000259A (en) 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) * 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
AU3439589A (en) 1988-03-24 1989-10-16 Terrapin Diagnostics, Inc. Molecular sticks for controlling protein conformation
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
CA2047042A1 (en) * 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
EP0542937A1 (en) 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
CA2161108A1 (en) 1993-04-23 1994-11-10 Herbert J. Evans Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US6287787B1 (en) * 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5675001A (en) 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
DE69521815T2 (de) 1995-05-04 2002-04-04 The Scripps Research Institute, La Jolla Proteinsynthese mittels nativer chemischer ligation (07.01.97)
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5849954A (en) * 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5849691A (en) * 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US5955893A (en) * 1996-12-16 1999-09-21 Macronix International Co., Ltd. Power saving buffer circuit buffer bias voltages
JP2002506423A (ja) * 1997-04-11 2002-02-26 イーライ・リリー・アンド・カンパニー ペプチド模倣型大員環のコンビナトリアルライブラリーとそのための方法
EP0989136A4 (en) 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk PEPTIDES WITH CYCLIC STRUCTURES THAT CAN RECOVER THE ACTIVITY OF MUTED P53 PROTEINS.
US7064193B1 (en) 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
WO2000052210A2 (en) 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
TR200102765T2 (tr) 1999-03-29 2002-05-21 The Procter & Gamble Company Melanokortin reseptör ligandları
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
WO2002013833A2 (en) 2000-08-16 2002-02-21 Georgetown University Medical Center SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
AU2002252246A1 (en) 2001-03-09 2002-09-24 University Of Louisville Helicomimetics and stabilized lxxll peptidomimetics
US20040106548A1 (en) 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
US7247700B2 (en) 2001-12-31 2007-07-24 Dana Farber Cancer Institute, Inc. BID polypeptides and methods of inducing apoptosis
WO2003059933A2 (en) 2002-01-03 2003-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conformationally constrained c-backbone cyclic peptides
AU2003211093A1 (en) 2002-02-15 2003-09-09 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
CA2487424C (en) 2002-05-30 2011-01-04 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
JPWO2004022766A1 (ja) * 2002-09-06 2005-12-22 株式会社カネカ Ｌ−α−メチルシステイン誘導体の製造方法
JP2006516383A (ja) 2002-09-09 2006-07-06 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３ペプチドおよびその使用方法
AU2003277891A1 (en) 2002-09-23 2004-04-08 Medivir Ab Hcv ns-3 serine protease inhibitors
ES2436296T3 (es) 2002-11-07 2013-12-30 Kosan Biosciences Incorporated Trans-9,10-dehidroepotilona C y trans-9,10-dehidroepotilona D, sus análogos y procedimientos de fabricación de las mismas
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
AU2003902743A0 (en) * 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides
WO2005007675A2 (en) 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE ϵ-AMINO ACIDS
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
CN1859904A (zh) * 2003-10-03 2006-11-08 默克公司 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
JP2007537989A (ja) 2003-10-16 2007-12-27 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化ペプチド
CA2830063C (en) 2003-11-05 2017-10-31 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
CN100335467C (zh) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 一锅法区域选择性合成5－碘代－1，4－二取代－1，2，3－三氮唑化合物
EP1602663A1 (en) 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
MX2007005176A (es) 2004-10-29 2007-06-25 Schering Corp 5-carboxiamida pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
CA2595902C (en) 2005-01-24 2017-08-22 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
EP2052253A2 (en) 2006-07-26 2009-04-29 Pepscan Systems B.V. Immunogenic compounds and protein mimics
WO2008033557A2 (en) 2006-09-15 2008-03-20 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclic peptidomimetics as integrin markers
AU2007319193A1 (en) 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
WO2008074895A1 (en) 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR20160061439A (ko) * 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP5883220B2 (ja) 2007-05-02 2016-03-09 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 細胞のホメオスタシス経路および細胞の生存を調節する方法
JP5653219B2 (ja) 2007-12-31 2015-01-14 ニューヨーク ユニバーシティ 水素結合サロゲートをベースとする人工ヘリックスによるウイルス宿主膜融合の制御
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP2011511076A (ja) 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
WO2009126292A2 (en) 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009149214A2 (en) 2008-06-03 2009-12-10 Aileron Therapeutics, Inc. Compositions and methods for enhancing cellular transport of biomolecules
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
EP2344520B1 (en) 2008-09-18 2013-11-13 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
EP2331567A1 (en) 2008-09-22 2011-06-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0918833A2 (pt) 2008-09-22 2015-12-08 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2010034026A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034034A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9206223B2 (en) 2008-09-22 2015-12-08 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
BRPI0920889A2 (pt) 2008-09-22 2017-10-10 Aileron Therapeutics Inc macrociclos peptidomiméticos.
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
US20110223149A1 (en) 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
CA2828889A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20130123196A1 (en) 2011-08-31 2013-05-16 New York University Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
WO2015157508A1 (en) 2014-04-09 2015-10-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2016049355A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX2017016251A (es) 2015-07-02 2018-04-20 Dana Farber Cancer Inst Inc Peptidos anti-microbianos estabilizados.
WO2017023933A2 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6971970B2 (ja) 2015-09-03 2021-11-24 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics, Inc. ペプチド模倣大環状分子およびその使用
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
JP2019520304A (ja) 2016-03-21 2019-07-18 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子に関するコンパニオン診断ツール
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
US20170360881A1 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Also Published As

Publication number Publication date
EP3170835A1 (en) 2017-05-24
US10328117B2 (en) 2019-06-25
JP2016199546A (ja) 2016-12-01
US20090047711A1 (en) 2009-02-19
US9675661B2 (en) 2017-06-13
BRPI0720306A2 (pt) 2014-02-04
US8609809B2 (en) 2013-12-17
WO2008076904A9 (en) 2017-04-27
CA2686827A1 (en) 2008-06-26
EP2094721A1 (en) 2009-09-02
CA2686827C (en) 2014-09-16
AU2007333846A1 (en) 2008-06-26
AU2007333846B2 (en) 2014-01-23
US20140135473A1 (en) 2014-05-15
US7960506B2 (en) 2011-06-14
CN105061577A (zh) 2015-11-18
CN101636407B (zh) 2015-08-26
JP6259861B2 (ja) 2018-01-10
IL199301A (en) 2014-09-30
US20160095896A1 (en) 2016-04-07
HK1137184A1 (en) 2010-07-23
EP2094721B1 (en) 2018-02-14
CN101636407A (zh) 2010-01-27
JP2010513314A (ja) 2010-04-30
US9175056B2 (en) 2015-11-03
WO2008076904A1 (en) 2008-06-26
JP2014231516A (ja) 2014-12-11
JP5931975B2 (ja) 2016-06-08
EP2094721A4 (en) 2011-01-19
US20170296620A1 (en) 2017-10-19
US20100184628A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
JP6259861B2 (ja) ビス−スルフヒドリル大環状化系
JP6194325B2 (ja) 改善された特性を有するペプチド模倣大環状分子
CN101663044B (zh) 三唑大环系统
JP6067626B2 (ja) ペプチド模倣大環状分子
HK1137184B (en) Bis-sulfhydryl macrocyclization systems
AU2017201310A1 (en) Bis-sulfhydryl macrocyclization systems

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140808

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141125

R150 Certificate of patent or registration of utility model

Ref document number: 5656407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees